Therapies modulating histamine pathways, specifically H1R, may help to regulate inflammation and improve outcomes in kidney diseases and neurodegenerative conditions [171,172]; GLP-1 mediates multiple comorbidities, but is particularly interesting as a therapeutic target in vascular diseases induced by diabetes [173]. This evidence concerns the gene GCG and kidney disorder.